Skip to content

APHP Plateform of Normothermic Perfusion for Rehabilitation of Hepatic Grafts

APHP Plateform for Assessement of Hepatic Grafts Initialy Discarded by Normothermic Perfusion

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04154696
Acronym
PENOFOR
Enrollment
20
Registered
2019-11-06
Start date
2019-10-28
Completion date
2022-04-01
Last updated
2019-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Keywords

Steatotic liver graft, Liver transplantation, Normothermic perfusion

Brief summary

This study aimed to evaluate fatty liver grafts, considered as unsuitable for upfront liver transplantation, by using normothermic perfusion. Grafts have to be allocated to one of 3 liver transplantation centres of Paris. After evidence of viability while on perfusion, these grafts will be transplanted to recipients with an estimated waiting time \> 6 months.

Detailed description

In this study, the coordinator investigator proposes to build a platform for perfusing in normothermic conditions all grafts with histologically proven macrosteatosis ≥ 30% that will be considered as unsuitable for upfront LT. These grafts have to be alloacted to one of the 3 liver transplantation centers of Assistance Publique des Hôpitaux de Paris. Eligible grafts (macrosteatosis ≥ 30%, no severe fibrosis or cirrhosis) will be shipped to the platform for normothermic perfusion. Perfusion will be started provided that cold ischemia time do not exceed 8 hours. Parameters of grafts viability (lactates, bile production, flow) will be monitored. After a minimum of 4 hours of normothermic perfusion (not exceeding 16 hours), grafts fulfilling strict criteria (homogeneous aspect of the liver without any necrotic regions, lactates \< 2.5 mmol/l and continuous production of bile with at least one of the following criteria: pH of perfusate \> 7.3, arterial flow \> 150 ml/min and portal flow \> 500 ml/min, homogeneous perfusion of the graft) will be considered suitable for transplantation. Recipient will be transferred to the operating room, and first phase of LT (i.e, laparotomy and total hepatectomy) will be started. Simultaneously, grafts will be shipped to the center of initial allocation. Perfusion will be pursued during the transport from the platform to the recipient. Recipients (≥18 years and ≤ 70 years) have to be enlisted for LT with an estimated waiting time \> 6 months (i.e., MELD score \< 25) and who signed an informed consent.

Interventions

PROCEDURELiver transplantation of a graft after assessment by normothermic perfusion

Liver transplantation of a graft after assessment by normothermic perfusion

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Liver transplantation of a graft after assessment by normothermic perfusion

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* patients enlisted for liver transplantation for liver disease or HCC (AFP score≤ 2); * Ongoing cotraception in women of reproductive age ; * Patient with social security ; * informed signed consent

Exclusion criteria

* Extra-hepatic tumor disease; * Re-transplantation ; * Pregnancy or brest-feeding; * Patients participting in another study; * Patients under psychiatric treatment; * Patients under tutorship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
To determine the proportion of grafts that can be transplanted after evaluation by normothermic perfusion (Hypothesis 50%) with a 3-year graft survival ≥ 90%3 monthsGraft survival

Secondary

MeasureTime frameDescription
Proportion of fatty grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period eligible for normothermic perfusion36 monthsProportion of fatty grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period eligible for normothermic perfusion
Proportion of grafts perfused36 monthsProportion of grafts perfused
Proportion of grafts that were transplanted after perfusion36 monthsProportion of grafts that were transplanted after perfusion
Time interval until liver function recovery while on normothermic perfusion (according to viability criteria defined above)15 hoursTime interval until liver function recovery while on normothermic perfusion (according to viability criteria defined above)
Proportions of grafts transplanted after normotheric perfusion wthout early allograft dysfunction (according to Olthoff definition)one monthProportions of grafts transplanted after normotheric perfusion wthout early allograft dysfunction (according to Olthoff definition)
Proportion of hepatic grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period36 monthsProportion of hepatic grafts allocated to the 3 transplant centres of Paris and considered as initially not transplantable during the study period
One-month overall survival (without retransplantation or graft dysfunction)one monthOne-month overall survival (without retransplantation or graft dysfunction)
One -year graft survivalone yearOne -year graft survival
Comparison of 3-months graft survival with a control group of graft considered as initially transplantable3 monthsComparison of 3-months graft survival with a control group of graft considered as initially transplantable
Waiting time between the two groups36 months
Incidence of biliary stenosis (anastomotic or non anastomotic) defined by cholangio MRI at one year12 monthsIncidence of biliary stenosis (anastomotic or non anastomotic) defined by cholangio MRI at one year
Time interval until liver function recovery after transplantationone dayTime interval until liver function recovery after transplantation

Countries

France

Contacts

Primary ContactRené ADAM, Pr
rene.adam@aphp.fr+ 33 1 45 59 30 49
Backup ContactMarc-Antoine Allard, Dr
marcantoine.allard@aphp.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026